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G protein-coupled receptors constitute the largest family of
membrane receptors and modulate almost every physiological
process in humans. Binding of agonists to G protein-coupled
receptors induces a shift from inactive to active receptor confor-
mations. Biophysical studies of the dynamic equilibrium of
receptors suggest that a portion of receptors can remain in inac-
tive states even in the presence of saturating concentrations of
agonist and G protein mimetic. However, the molecular details
of agonist-bound inactive receptors are poorly understood.
Hereweuse themodel of bitopic orthosteric/allosteric (i.e.dual-
steric) agonists for muscarinic M2 receptors to demonstrate the
existence and function of such inactive agonistreceptor com-
plexes on amolecular level. Using all-atommolecular dynamics
simulations, dynophores (i.e. a combination of static three-di-
mensional pharmacophores and molecular dynamics-based
conformational sampling), ligand design, and receptor mu-
tagenesis, we show that inactive agonistreceptor complexes
can result from agonist binding to the allosteric vestibule alone,
whereas the dualsteric bindingmode produces active receptors.
Each agonist forms a distinct ligand binding ensemble, and dif-
ferent agonist efficacies depend on the fraction of purely allos-
teric (i.e. inactive) versus dualsteric (i.e. active) binding modes.
We propose that this concept may explain why agonistreceptor
complexes can be inactive and that adopting multiple binding
modes may be generalized also to small agonists where binding
modes will be only subtly different and confined to only one
binding site.
Specific and coordinated cell-to-cell communication regu-
lates the flow of information between cells, and proper infor-
mation processing ensures physiological functions of biological
systems. G protein-coupled receptors (GPCRs),8 constituting
the largest class of membrane proteins in mammals, are essen-
tial mediators of chemically and light-encoded information
(1–4). GPCRs sense a great variety of extracellular stimuli, e.g.
neurotransmitters and hormones, and subsequently translate
this information into an intracellular response via G proteins,
-arrestins, and possibly GPCR-interacting proteins (2–5).
Because of their abundance and relevance in regulating the
majority of (patho-)physiological processes in humans, GPCRs
have for a long time represented the most important drug tar-
gets being addressed by at least a third of all currentlymarketed
drugs (6, 7).
Agonist binding leads to receptor activation, which is fol-
lowed by intracellular G protein recruitment and subsequent
cell signaling. Breakthroughs in GPCR crystallography have led
to inactive and active crystal structures of the same receptor
protein. Among these are rhodopsin (8–10) and more recently
the 2-adrenergic (11–14), M2 muscarinic (15, 16), and -opi-
oid receptors (17, 18). These structures most likely represent
energetically favored, relatively stable inactive and active
receptorligand complexes. Despite the diversity of crystallized
receptors, a common mechanism of receptor activation can be
inferred from these structures in conjunction with a wealth of
older biochemical data. Agonist-mediated receptor activation
leads to an outward tilt of the intracellular parts of transmem-
brane helices V andVI, facilitating intracellular G protein bind-
ing, which in many cases is accompanied by an inward move-
ment of the extracellular parts of transmembrane helices V and
VI. This results in a contraction of the ligand binding site, clos-
ing it off toward the extracellular space.
Despite the wealth of GPCR structures, however, little is
known about the structural dynamics of their inactive-to-active
transitions and different agonist efficacies. Recent biophysical
studies on various receptors (Class A and Class C) have shown
thatGPCRs reside in a dynamic equilibriumof distinct receptor
conformations comprising inactive and active receptor states
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(19–22). These studies suggest a commonmechanism for ago-
nist efficacy: agonists shift the preexisting equilibrium of differ-
ent receptor conformations toward more active states (21, 22).
Interestingly, the dynamic equilibrium of receptors remains
heterogeneous even in the presence of saturating concentra-
tions of full agonists and always contains a fraction of receptors
in inactive states (19, 21–23). In fact, agonists alone are not
sufficient to stabilize the fully active receptor state as seen in the
crystal structures (19–24). The fully active state is only reached
upon addition of both saturating concentrations of agonist and
a G protein or nanobody (19, 21, 23). However, even under
these conditions, e.g. in the presence of the full agonist isopro-
terenol and the nanobody Nb80, a significant percentage of
2-adrenergic receptors still remains in inactive states (21).
In line with this concept, partial agonists would stabilize
fewer receptors in active states, and concomitantly a greater
fraction of partial agonist-bound receptors would remain in
inactive states (22, 24). However, it is puzzling how agonist-
bound receptors can adopt active and inactive states. Based on
the above mentioned evidence that receptors are “floppy,” it is
reasonable to hypothesize that agonists may have multiple
binding modes; some of these agonist binding modes might
then stabilize active agonistreceptor complexes, whereas other
agonist bindingmodesmight stabilize inactive agonistreceptor
complexes.
However, because purely orthosteric partial agonists are
likely to show only slightly different binding modes, it is tech-
nically challenging to investigate this phenomenon with cur-
rent methods. In this study, we make use of a special case of
agonism to identify multiple binding topographies of agonists
and to provide a proof of principle that ligand binding ensem-
bles can form themolecular basis of different agonist efficacies.
This special case is dualsteric partial agonists for themuscarinic
M2 receptor (M2AChR) that comprise two pharmacophores
targeting the orthosteric and allosteric binding sites, respec-
tively (25). These dualsteric agonists have been suggested to
possess two pharmacologically distinct binding modes (26–
28), a feature defined as dynamic ligand binding (28). The
“extreme”molecular nature of the dualsteric agonists, i.e. span-
ning two binding sites, is anticipated to allow the identification
of distinct ligand binding topographies.
By combining pharmacologicalmethods,molecular docking,
and all-atom molecular dynamics simulations based on
M2AChR crystal structures, we here identify two distinct bind-
ing topographies of a set of dualsteric partial agonists. One
binding mode resembles that of the co-crystallized orthosteric
agonist iperoxo (16) and forms an active agonistreceptor com-
plex. The other binding mode is purely allosteric and forms an
inactive agonistreceptor complex by adopting binding topog-
raphies similar to those of common allosteric modulators (29).
We show that both types of agonistreceptor complexes are
present in a receptor population at the same time. Manipula-
tion of the dynamic equilibrium of active and inactive
agonistreceptor complexes by ligand design and by mutations
reveals that the fraction of inactive agonistreceptor complexes
decreases overall agonist efficacy.
Our findings suggest that an ensemble of active and inactive
agonistreceptor complexes in which agonists adopt multiple
binding topographies is a molecular basis for different agonist
efficacies. Albeit having studied a highly specific case of GPCR
agonism, our findings provide general evidence for the concept
that agonists can principally stabilize inactive agonistreceptor
complexes; this may also apply to agonists that target only one
binding site of the receptor.
Results
Direct Pharmacological Evidence forMultiple BindingModes
of a Dualsteric Agonist—Dualsteric (also termed bitopic
orthosteric/allosteric) ligands (30) for muscarinic receptors are
composed of orthosteric and allostericmoieties covalently con-
nected via linkers of different chemical nature (31–34). Recent
studies suggested that at least some of these bipharmacophoric
ligands may have more than one binding mode (28, 34). The
experimental results are compatible with a theoretical scenario,
i.e. dynamic ligand binding, in which such a ligand would adopt
a dualsteric pose (Fig. 1a) and a purely allosteric binding mode
(Fig. 1a). In this study, we provide direct evidence that iper-6-
naph indeed displays two distinct binding modes at M2AChRs.
Iper-6-naph is a prototypical dualsteric ligand (Fig. 1a) that is
composed of the orthosteric agonist iperoxo linked via a hex-
amethylene chain to an allosteric modulator derived from
naphmethonium. Equilibrium binding of iper-6-naph using
N-[3H]methylscopolamine ([3H]NMS) as the orthosteric radio-
tracer shows partial displacement of [3H]NMS in a HEPES
buffer (10 mM HEPES, 10 mM MgCl2, 100 mM NaCl) (Fig. 1b).
[3H]NMS displacement indicates ligand competition between
iper-6-naph and the radioligand at the orthosteric site. How-
ever, the incomplete [3H]NMSdisplacement at high concentra-
tions of iper-6-naph is indicative of the formation of ternary
complexes consisting of [3H]NMS and iper-6-naph bound to
the receptor’s orthosteric and allosteric sites, respectively. The
binding of iper-6-naph to the allosteric site hampers [3H]NMS
dissociation, which is detected as incomplete displacement
(Fig. 1b). To directly prove that iper-6-naph can indeed adopt a
purely allosteric binding pose, we conducted [3H]NMS dis-
placement experiments in a 5 mM Na, K, Pi buffer (for exact
composition see “Experimental Procedures”). This buffer has
been shown to increase the affinity of various allosteric modu-
lators, most likely due to the absence of Mg2 cations, which
have been suggested to compete with allosteric modulators for
the allosteric binding site at muscarinic M2 receptors (35).
Under these conditions, iper-6-naph leads to a concentration-
dependent increase of [3H]NMS binding, which is direct evi-
dence for an allosteric binding topography of iper-6-naph (Fig.
1b). On the molecular level, enhancement of [3H]NMS binding
is due to positive cooperativity of the allosteric moiety 6-naph
with [3H]NMS (Fig. 1c). The 5 mMNa, K, Pi buffer enhances
both allosteric affinity and efficacy of 6-naph (Fig. 1c). However,
the 5mMNa, K, Pi buffer has little to no effect on the binding
of the orthosteric agonist iperoxo (Fig. 1d). These data demon-
strate that iper-6-naph adopts two distinct binding modes at
M2AChRs that reside in dynamic equilibrium.
Structural Characteristics of a Ligand Binding Ensemble—
The concept that ligands can adopt multiple distinct binding
modes at the same GPCR has been defined as dynamic ligand
binding (28) (Fig. 1a). However, the structural basis for this
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phenomenon remains unclear. To demonstrate that a GPCR is
indeed capable of accommodating a ligand in multiple binding
modes, i.e. forming a ligand binding ensemble, we here apply an
interdisciplinary approach combining molecular modeling
techniques guided by pharmacological experiments and vice
versa. Our modeling strategy consists of a combination of all-
atommolecular dynamics (MD) simulations and three-dimen-
sional pharmacophores (36, 37).
TheM2AChRdisplays strong allosteric coupling between the
ligand binding site and the intracellular G protein-binding
interface (16). Structurally, this is represented by a pronounced
contraction of the orthosteric binding site (16). In fact, iperoxo
binding leads to a complete closure of the orthosteric binding
site toward the extracellular space (16). The so-called tyrosine
lid formed by Tyr-1043.33, Tyr-4036.51, and Tyr-4267.39 sepa-
rates the orthosteric binding site from the allosteric binding site
in the activeM2AChR crystal structures (Fig. 2a). However, the
side chain conformations of these tyrosine residues appear very
flexible in MD simulations, and the receptor tolerates agonist
bindingwithin an orthosteric binding site that is not completely
closed. Based on the available crystal structures of theM2AChR
in active (Protein Data Bank codes 4MQS and 4MQT) (16) and
inactive conformations (Protein Data Bank code 3UON) (15),
we first generated receptorligand complexes by docking exper-
iments. To dock iper-6-naph into the activeM2AChR structure
(Protein Data Bank code 4MQT), the tyrosine lid was remod-
eled by side chain sampling based on MD simulations of the
iperoxo-bound crystal structure (Fig. 2, b and c). MD-based
side chain sampling detects an open tyrosine lid suitable for
docking bitopic agonists. The only differences between the
crystal structure and the obtained active-like receptor model
are the side chain conformations of Tyr-1043.33, Tyr-4036.51,
and Tyr-4267.39.
Docking and subsequent all-atom MD simulations initiated
froman active receptorligand complex reveal a dualsteric bind-
ing topography of iper-6-naph (Fig. 3a). The iperoxo moiety of
iper-6-naph binds to the orthosteric binding site, whereas the
6-naph moiety protrudes toward extracellular domains,
thereby engaging residues of the common allosteric binding
site (Fig. 3a). The dualsteric binding pose of iper-6-naph stabi-
lizes an active ligandreceptor complex because the agonistic
properties of iper-6-naph are mediated by the orthosteric site
(25) and hence are only compatible with a binding pose in
which the iperoxo moiety targets the orthosteric binding site.
Based on theMD simulations, additionalmolecular descriptors
can be inferred that argue for an active ligandreceptor com-
plex. First, the orientation of the iperoxomoiety of iper-6-naph
is almost identical to that observed in the iperoxo-bound
M2AChR crystal structure (Fig. 3, a and b). In both iperoxo and
iper-6-naphMD simulations of the activeM2AChR complexes,
FIGURE 1. Iper-6-naph adopts two distinct bindingmodes. a, theory of dynamic ligand binding. The partial agonist iper-6-naph consists of two pharmaco-
phores, one active (green triangle) and one inactive (blue square) moiety connected by a flexible linker (black zigzag line). Dynamic ligands may bind to a
receptor population in two distinct orientations, the dualsteric binding pose and the purely allosteric binding pose (see the receptor on the left and right sides,
respectively). In the dualsteric pose, the active moiety binds to the orthosteric binding site (green ellipsoid), and the inactive moiety binds to the allosteric
binding site (cyan ellipsoid). Receptors bound to iper-6-naph in thedualsteric pose induce receptor activation. In thepurely allosteric bindingpose, iper-6-naph
resides entirely in the allosteric binding site, precluding receptor activation.b–d, equilibriumbindingof iper-6-naph (b), the allosteric ligand6-naph (c), and the
orthosteric agonist iperoxo (d) competing against the orthosteric probe [3H]NMS to M2AChRs from CHO membranes in HEPES buffer (filled squares) and in
Na/K/Pi buffer (open squares). Total binding in the absence of test compounds was set to 100%. Data are means  S.E. from at least four independent
experiments conducted in triplicate. Error bars represent S.E.
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the positively charged nitrogen of iperoxo interacts with Asp-
1033.32 and displays -cation interactions with Tyr-1043.33,
Tyr-4036.51, and Tyr-4267.39 (Fig. 3, a and b). The triple bond
exhibits hydrophobic contacts with Tyr-1043.33, Trp-1554.57,
and Trp-4006.48. Additionally, Asn-4046.52 forms a hydrogen
bond with the oxygen of the 4,5-dihydroisoxazole moiety of
iperoxo (Fig. 3a). Second, the volume of the orthosteric binding
site of iper-6-naphreceptor complexes (249.6 Å3) is similar to
the orthosteric volume of the active iperoxoreceptor structure
(222.3 Å3) and that obtained by MD simulation of active
iperoxoreceptor complexes (242.7 Å3). In line with this, the
distance between the C atoms of Tyr-1043.33 and Asn-4046.52
as an indicator for the extent of contraction of the orthosteric
binding site upon activation is similar in the iper-6-naph (13.1
Å) and iperoxoMDsimulations (12.4Å). In contrast, the crystal
structure of the inactive M2AChR shows a larger volume of the
orthosteric binding site (383.6 Å3) and a larger distance
between Tyr-1043.33 and Asn-4046.52 (13.6 Å).
Docking of iper-6-naph into the inactive M2AChR crystal
structure (Protein Data Bank code 3UON) and subsequentMD
simulations reveal a second bindingmode of iper-6-naph that is
purely allosteric (Fig. 3c). Overall, the purely allosteric binding
pose of iper-6-naph is similar to that of the allostericmodulator
naphmethonium (Fig. 3d). Iper-6-naph in its purely allosteric
binding mode interacts with two centers formed by aromatic
residues in the allosteric vestibule (Fig. 3c). The first center is
lined by Tyr-177EL2 and Trp-4227.35, and the second is lined by
Tyr-802.60 and Tyr-832.63 as reported previously for prototypi-
cal allosteric modulators (29). In line with this, the ammonium
group of the iperoxo moiety forms cation- interactions with
Tyr-802.60 and Tyr-832.63, and the other ammonium group dis-
plays cation- interactions with Trp-4227.35 (Fig. 3, c and d). In
addition, the triple bond is located opposite to Tyr-177EL2, and
the two methyl groups of the small allosteric linker chain show
lipophilic contacts to Ala-1915.43, Tyr-4036.51, and Tyr-4267.39
(Fig. 3c). The naphthalene ring is embedded in a pocket built
by Thr-1875.39, Phe-1885.40, and Val-4076.55. Moreover, the
ammonium group of iperoxo forms a charge interaction with
Glu-175EL2, and the other ammonium group features cation-
interactions with Trp-993.28 and Tyr-4267.39 (Fig. 3, c and d).
Functionally, the allosteric binding pose of iper-6-naph sta-
bilizes an inactive ligandreceptor complex as its topography is
comparable with the allosteric ligand naphmethonium (Fig.
3d). Naphmethonium and, in particular, its building block
6-naph are allosteric inverse agonists (28). OurMD simulations
indicate that iper-6-naph is able to adopt two completely dis-
tinct binding modes at the same receptor: the dualsteric iper-
6-naphM2AChR complex resembles an active receptor,
whereas the purely allosteric iper-6-naphM2AChR complex is
inactive.
We use pharmacological experiments to quantify the frac-
tions of receptors that are bound to iper-6-naph in either the
dualsteric or the allosteric binding pose (Fig. 3e). [35S]GTPS
binding experiments are used to detect ligand agonism, which
FIGURE 2. Remodeling of the tyrosine lid. a, transmembrane view of the activeM2AChR crystal structure with the orthosteric agonist iperoxo (green surface)
and the positive allosteric modulator LY2119620 (cyan surface). The tyrosine lid that separates the orthosteric and allosteric binding sites is shown in red.
Allosteric key residues are shown in orange. b, top view snapshots from an MD simulation of the iperoxo-bound crystal structure unveil the conformational
flexibility of the tyrosine lid, especially tyrosine Tyr-4267.39. c, based on the sampling of side chain conformations, the tyrosine lid was remodeled for binding
mode investigations on dualsteric agonists.
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is mediated by iper-6-naph bound to the receptors in the dual-
steric binding mode. [3H]NMS equilibrium binding experi-
ments provide data on iper-6-naph’s binding ensemble. By
globally analyzing [3H]NMS and [35S]GTPS binding data of
iper-6-naph, we directly quantify the fractions of active and
inactive receptors as well as iper-6-naph’s affinities KA and KB
(equilibrium dissociation constants) for the dualsteric active
and the allosteric inactive binding modes, respectively. More-
FIGURE 3. Structural characteristics of a ligand binding ensemble. Transmembrane view of representative conformations of M2AChR complexes with the
dynamic ligand iper-6-naph (a and c) in two distinct binding orientations, dualsteric (a) and purely allosteric (c). The boxed parts of a and c illustrate in more
detail ligand-receptor interactions by three-dimensional pharmacophores. Yellow spheres indicate lipophilic contacts, red arrows indicate hydrogen bond
acceptors, the purple disk represents a -stacking interaction, and positively charged centers are shown as blue spheres. b, comparison of iperoxo in its
co-crystallized conformation (dark gray) with the orthosteric part of iper-6-naph from an MD simulation (light gray). d, comparison of the binding orientation
in the allosteric vestibule of naphmethonium (dark gray) with iper-6-naph (light gray) with key residues for allosteric ligandbinding. e, effects of iper-6-naphon
[3H]NMS equilibrium binding in HEPES buffer (orange curve) and iper-6-naph-induced M2AChR-mediated G protein activation measured as incorporation of
[35S]GTPS into membranes of CHO-M2AChR cells (green curve). ACh-stimulated [
35S]GTPS binding (gray curve) defined the maximum effect of the system
(set to 100%). Basal [35S]GTPS binding in the absence of ligands was set to 0%. [3H]NMS and [35S]GTPS binding were plotted on the left and right ordinates,
respectively. Data represent mean  S.E. from four to eight independent experiments conducted in triplicate. f, the fractional population of active
agonistreceptor complexes (factive; orange bar) and the overall efficacy of iper-6-naph (Emax; green bar) were plotted on the left and right ordinates, respectively.
factive was retrieved by fitting all data points in e globally to an operational model of agonism for dynamic ligands (see “Experimental Procedures”). Error bars
represent S.E.
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over, the global analysis yields the dynamic efficacy, dyn, of
iper-6-naph (for fitting details see “Experimental Procedures”).
This new global analysis is superior to previous analyses (25, 26,
28, 34) as it yields the allosteric affinity KB of a dualsteric ligand
that has not been experimentally accessible before. Iper-6-naph
displays partial M2AChR activation in relation to acetylcholine
(ACh), which defines the maximal effect of the system (Fig. 3, e
and f). Global analysis yields a significantly higher affinity of
iper-6-naph for the dualsteric than for the allosteric binding
mode (pKA and pKB are 7.40  0.06 and 6.84  0.06, respec-
tively; p 0.001, unpaired t test). Consequently, the fraction of
active iper-6-naphreceptor complexes, factive (Fig. 3f), is signif-
icantly higher than the inactive fraction (79 versus 21%, p 
0.001).
Decrease of Agonist Efficacy Is Due to an Increase of Inactive
Agonist-Receptor Complexes—We provide structural evidence
that the ligand’s preference for the purely allosteric binding
mode determines its efficacy.We apply isox-6-naph, which dif-
fers from iper-6-naph only in its orthosteric moiety (for the
molecular structures of all compounds see Fig. 4). Isox, the
orthosteric building block of isox-6-naph, is a derivative of iper-
oxo displaying equal efficacy atmuscarinic receptors albeit hav-
ing a 100-fold lower affinity. Docking andMD simulations indi-
cate that the topographies of iperoxo and isox in the orthosteric
binding site of active M2AChR complexes are highly similar
(Fig. 5, a and b). However, different hydrogen bond strengths
were reported for furan and isoxazole compared with non-aro-
matic ring systems (38, 39). Therefore, we expected a higher
occurrence of geometries related to hydrogen bonds in the sim-
ulation of the iperoxo-bound M2AChR complex. To unveil
these differences, we generated three-dimensional interaction
point densities (dynophores) by MD-based sampling (Fig. 5c).
Following this approach, we find that iperoxo forms a hydrogen
bond to the orthosteric epitope Asn-4046.52 in nearly all frames
of the trajectory (98%), whereas isox shows this interaction in
only 87% of the frames. Further analyses of hydrogen bond dis-
tances and angle frequencies confirm this observation, showing
nearly ideal geometry for iperoxo, whereas for isox more devi-
ations are observed (Fig. 5c). All other interactions show no
difference between iperoxo and isox (Fig. 5b). Docking andMD
simulations of M2AChR complexes bound to isox-6-naph in
the dualsteric mode reveal overall homology to iper-6-naph
(Fig. 5d). However, the dynophore analysis of iper-6-naph and
isox-6-naph in their dualsteric binding modes reveals a similar
occurrence of hydrogen bonds (98 versus 90%) as for the
orthosteric building blocks iperoxo and isox (98 versus 87%).
Hence, the topographical differences between iperoxo and isox
(Fig. 5c) are preserved in the topographies of their dualsteric
ligands iper-6-naph and isox-6-naph, respectively. In line with
these structural data, global analysis of [3H]NMS equilibrium
binding and [35S]GTPS binding data reveals a 100-fold lower
affinity of isox-6-naph than iper-6-naph in their dualsteric
binding modes as reflected by pKA(isox-6-naph) 5.12 0.15
and pKA(iper-6-naph) 7.40 0.06, respectively (Fig. 5f).
Isox-6-naph has recently been shown to be a less efficacious
partial agonist than iper-6-naph (28). MD simulations of isox-
6-naph in its allosteric binding mode reveal an unexpected
intramolecular interaction. The isox moiety forms a - inter-
action with the allosteric moiety 6-naph that is not possible in
the purely allosteric binding mode of iper-6-naph. This stabi-
lizes an intramolecular conformation of isox-6-naph that is
likely to bind with high affinity to the allosteric vestibule (Fig.
5e). In fact, the ammonium group of the isox moiety forms a
charge interaction with Glu-175EL2. The other ammonium
group displays cation- interactions with Tyr-802.60 and Tyr-
4267.39. The triple bond lies opposite Tyr-177EL2, and the two
methyl groups of the small allosteric linker chain show lipo-
philic contacts to Ile-178EL2 and Tyr-4267.39. The naphthalene
ring is embedded in a pocket lined by Phe-181EL2, Tyr-177EL2,
and Thr-1875.39. Additionally, Ile-178EL2 is able to form a
hydrogen bond to one of the carbonyl groups of the allosteric
moiety (Fig. 5e). This allosteric network suggests an optimal fit
of isox-6-naph to the allosteric binding site. Indeed, global
pharmacological analysis (Fig. 5f) yields a significantly higher
affinity of isox-6-naph for the inactive than for the active pose
(pKB and pKA are 7.11 0.15 and 5.12 0.15, respectively; p
0.001, unpaired t test). This results in an almost exclusive allos-
teric binding topography of isox-6-naph (99 versus 1% for the
FIGURE 4.Molecular structures of all chemical probes.
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inactive and active fraction, respectively; p 0.001, unpaired t
test).
Overall, isox-6-naph binds to the allosteric binding site with
higher affinity than to the orthosteric binding site. Isox-6-
naph’s preference for the purely allosteric binding mode
explains its lower efficacy compared with iper-6-naph (Fig. 5f).
Increase of Agonist Efficacy Is Due to a Decrease of Inactive
Agonist-Receptor Complexes—Iper-8-naph is a dualsteric
ligand in which the orthosteric and allosteric building blocks
are connected via an octamethylene linker. MD simulations of
iper-6-naph (Fig. 3c) and isox-6-naph (Fig. 5e) in their purely
allosteric bindingmodes imply that a longer linker would ham-
per a purely allosteric binding mode of iper-8-naph. Indeed,
MD simulations of allosterically bound iper-8-naphM2AChR
complexes show a suboptimal topography of iper-8-naph in the
allosteric binding site (Fig. 6a). Although iper-8-naph shares
some key interactions with iper-6-naph (Fig. 3c) and isox-6-
naph (Fig. 5e), its overall, purely allosteric topography is distinct
(Fig. 6a). Moreover, its orientation in the allosteric binding site
appears to be variable. Heavy atoms of iper-8-naph show a pro-
nounced deviation of its docking pose during the simulation
time. In contrast, iper-6-naph and even more so isox-6-naph
remain in their orientation (Fig. 6b). However, MD simulations
of dualsterically bound iper-8-naphM2AChR complexes show
homology to the dualsteric poses of iper-6-naph and isox-6-
naph. Global analysis of pharmacological data reveals that first
a higher affinity of iper-8-naph for the dualsteric, active than for
the allosteric, inactive pose (pKA and pKB are 8.50  0.06 and
6.87 0.06, respectively; p 0.001, unpaired t test), second the
fraction of active receptors is significantly greater than the frac-
tion of inactive receptors (98 versus 2%; p  0.001, unpaired t
test), and third the efficacy of iper-8-naph resembles that of a
full agonist (Fig. 6, c and d). Overall, a dualsteric ligand’s pref-
erence for the dualsteric binding mode increases its efficacy.
FIGURE 5. Decrease of agonist efficacy is due to the preference for the purely allosteric binding mode. a, comparison of iperoxo in its co-crystallized
conformation (dark gray) with isox from anMD simulation (light gray). The yellow spheres indicate lipophilic contacts, the red sphere indicates a hydrogen bond
acceptor, and the positively charged center is shown as a blue star. b, similar pharmacophoric features of iperoxo (above) and isox (below) with key residues for
ligand binding. The yellow spheres indicate lipophilic contacts, the red sphere indicates a hydrogen bond acceptor, and the positively charged center is shown
asablue star. c, the combinationof three-dimensional pharmacophores andMDsimulations led to thenewconceptofdynophores (dynamicpharmacophores)
that are able to reflect time-dependent changes in the interaction pattern of ligands. The yellow cloud indicates lipophilic contacts, the red cloud indicates a
hydrogen bond acceptor, and the positively charged center is shown as a blue cloud. Whereas the positively charged center and the lipophilic contacts could
beobserved inall framesof theMDsimulation, thehydrogenbondacceptor featurewaspresent in almost all frames (98%) for iperoxoand iper-6-naphbutonly
in 87% of all frames for isox and 90% for isox-6-naph. Below, relative frequencies of distance and angle of the hydrogen bond acceptor. Curves for iperoxo and
iper-6-naph are shown in black; curves for isox and isox-6-naph are shown in gray. d, the dualsteric bindingmodes of iper-6-naph (dark gray) and isox-6-naph
(light gray) are highly similar. e, three-dimensional pharmacophore analyses of isox-6-naph in the purely allosteric bindingmode. Note that isox-6-naph forms
an intramolecular - stacking interaction between the isoxazole moiety and the allosteric ring system. f, effects of isox-6-naph on [3H]NMS equilibrium
binding inHEPESbuffer (orange curve) andGprotein activation (green curve). [3H]NMSand [35S]GTPSbindingdatawereplottedon the left and right ordinates,
respectively. Data represent mean S.E. from four to seven independent experiments conducted in triplicate. Error bars represent S.E.
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An Allosteric Triple Mutant Rescues Agonist Efficacy—For
decades, the M2AChR has served as the paradigm for the study
of allosteric modulation at GPCRs. Based on mutagenesis and
recent computational studies, key epitopes of the allosteric
binding site are well known (29, 40–42). To modulate the
ensemble of dynamic ligands bound to M2AChRs, we mutated
an allosteric center that is lined by Tyr-177EL2, Trp-4227.35, and
Thr-4237.36 (Fig. 2a). This mutation does not affect the affinity
of [3H]NMS (pKD values are 9.28  0.04 and 9.21  0.02 for
wild type and mutant receptors, respectively). However, the
affinity of the agonists ACh and iperoxo is significantly reduced
(Fig. 7a). This is most likely due to the absence of Trp-4227.35,
which reorientates upon receptor activation and is required to
stabilize the fully active state of theM2 receptor (16). [3H]NMS
equilibriumbinding experimentswith dualsteric ligands showa
complete displacement of [3H]NMS by both ligands iper-6-
naph (Fig. 7c) and isox-6-naph (Fig. 7d). This indicates that the
dualsteric binding mode is preferred at allosterically mutated
receptors (Fig. 7e). In line with this, [35S]GTPS binding exper-
iments show higher efficacy of iper-6-naph (Fig. 7, c and f) and
isox-6-naph (Fig. 7, d and f) at allosteric mutant than at wild
type receptors (receptor expression levels (in pmol/mg of pro-
tein) are not significantly different (p  0.92, unpaired t test):
3.9  0.75 and 3.8  0.65 for wild type and mutant receptors,
respectively). The efficacy of ACh and iperoxo is equal at both
receptors (Fig. 7b). Global analyses of [3H]NMS and
[35S]GTPS binding data of iper-6-naph (Fig. 7c) and isox-6-
naph (Fig. 7d) further reveal increased operational efficacies
(log dyn) of iper-6-naph and isox-6-naph at mutant M2AChRs
(iper-6-naph, 0.34  0.04 versus 0.77  0.08; isox-6-naph,
2.11  0.36 versus 0.14  0.11 for wild type and mutant
receptors, respectively; p  0.001, unpaired t test). Taken
together,mutational disruption of an allosteric center increases
the ligand’s preference for the dualsteric binding mode and
hence rescues agonist efficacy.
Rational Design of a Full Agonist with Exclusive Dualsteric
Binding Topography—Dynamic ligand binding to M2AChRs is
characterized by a binding mode ensemble comprising active
and inactive ligandreceptor complexes bound to the same
ligand in a dualsteric and an allosteric binding mode, respec-
tively (Fig. 3). Both ligandreceptor complexes are in equilib-
rium, the position of which is sensitive to the affinity to both the
orthosteric and allosteric binding sites (Figs. 1, 5, 6, and 7). This
implies that it should be possible to design a putatively dual-
FIGURE 6. Increase of agonist efficacy is due to the preference for the dualsteric bindingmode. a, three-dimensional pharmacophore analysis of iper-8-
naph in the purely allosteric binding mode. Yellow spheres indicate lipophilic contacts, red arrows indicate hydrogen bond acceptors, and positively charged
centers are shown as blue spheres. b, deviation of heavy atoms during 50 ns of MD simulation. Whereas isox-6-naph (blue curve) and iper-6-naph (green curve)
remain in their orientation, iper-8-naph (gray curve) poorly fits into the allosteric vestibule. c, effect of iper-8-naph on [3H]NMS equilibrium binding in HEPES
buffer (orange curves) and G protein activation (green curves). [3H]NMS and [35S]GTPS binding were plotted on the left and right ordinates, respectively. Data
representmean S.E. from four to seven independent experiments conducted in triplicate. d, the fractional population of active agonist receptorcomplexes
(factive) stabilized by the indicated dynamic ligands (orange bars) and their overall efficacy (Emax; green bars) relative to ACh were plotted on the left and right
ordinates, respectively. factive was retrieved by fitting all data points in Figs. 5f and 6c globally to an operational model of agonism for dynamic ligands. *** and
###, significantly different from iper-6-naph with regard to factive and Emax, respectively (p  0.001, one-way analysis of variance and Bonferroni’s multiple
comparison test). Error bars represent S.E.
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steric ligand that does not bind to the receptor in the purely
allosteric mode anymore and hence should display full ago-
nism. Based on our structural model, we estimated the very
extreme distance within the allosteric vestibule to be 15.7 Å,
measured between Thr-842.65 and Thr-1875.39 (Fig. 8b). Here-
upon, we designed and synthesized the ligand iper-rigid-naph
(for chemical synthesis, see supplemental Fig. 1). Iper-rigid-
naph is a derivative of iper-6-naph comprising a linker that is
longer (16.0 Å) and more rigid than the hexamethylene and
octamethylene spacers (Fig. 8b). Attempts to dock iper-rigid-
naph only into the allosteric vestibule of inactive M2AChRs
failed due to multiple clashes with allosteric residues (Fig. 8b).
In contrast, molecular docking and MD simulations of active
M2AChR complexes indicate that iper-rigid-naph keeps the
dualsteric binding mode, resulting in full receptor activation
(Fig. 8a). The suggested loss of an allosteric binding pose of
iper-rigid-naph is corroborated by pharmacological experi-
ments (Fig. 8c). Global analysis of [3H]NMS and [35S]GTPS
binding data indicates that iper-rigid-naph exclusively stabi-
lizes activeM2AChRs (Fig. 8d). In linewith this, iper-rigid-naph
displays full agonism (Fig. 8d).
Discussion
GPCRs are highly flexible membrane proteins (43, 44),
adopting a multitude of distinct conformations (inactive and
active) even in the absence of ligands (19–22, 24). Agonist bind-
ing leads to a shift of the receptor’s conformational equilibrium
toward active states. The equilibrium shift, however, is not
FIGURE 7.Mutational disruption of an allosteric center increases the fraction of active ligandreceptor complexes. a, equilibrium binding of ACh and
iperoxo to hM2 wild type (filled squares) and triple mutant receptors (open squares) competing against the orthosteric probe [
3H]NMS. Total binding in the
absence of test compoundswas set to 100%.Data aremeans S.E. fromat least three independent experiments conducted in triplicate.b, [35S]GTPSbinding
mediated by hM2 wild type (filled squares) and triple mutant receptors (open squares) reflects receptor activation induced by ACh and iperoxo. [
35S]GTPS
binding in the absence of ligand was set to 0%, and maximal ligand-induced [35S]GTPS binding was set to 100%. Data are means S.E. from at least four
independent experiments conducted in triplicate. c andd, displacement of [3H]NMSequilibriumbinding (orange curves) by iper-6-naph (c) and isox-6-naph (d)
in HEPES buffer and G protein activation (green curves). For comparison, [3H]NMS equilibrium and [35S]GTPS binding data fromwild type CHO-M2AChR cells
are shown in orange and green dashed lines, respectively. [3H]NMS and [35S]GTPS binding were plotted on the left and right ordinates, respectively. Data in c
and d represent mean  S.E. from four to eight independent experiments conducted in triplicate. e, the fractional population of active M2AChRs (factive)
stabilized by the indicated dynamic ligands at hM2 wild type (empty bars) and hM2 triple mutant (filled bars) receptors. f, maximal agonist efficacies (Emax)
relative to Ach of the indicated ligands at wild type (empty bars) and allosteric triple mutant (filled bars) receptors. Error bars represent S.E.
Ligand Binding Ensembles Determine Graded Agonist Efficacies
JULY 29, 2016•VOLUME 291•NUMBER 31 JOURNAL OF BIOLOGICAL CHEMISTRY 16383
 at U
niversità degli studi di M
ilano on N
ovem
ber 15, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
quantitative. Even in the presence of a G protein mimetic, ago-
nist-occupied receptors can adopt inactive states (21).
We have studied the existence, molecular details, and func-
tion of such inactive agonistreceptor complexes. Bitopic partial
agonists for M2AChRs adopt a ligand binding ensemble con-
sisting of a dualsteric and a purely allosteric binding mode (Fig.
3). Dualsterically bound agonistreceptor complexes induce
G protein activation, whereas purely allosterically bound
agonistreceptor complexes are inactive (Fig. 3). Multiple lines
of evidence imply that both states reside in dynamic equilib-
rium (Figs. 1, 5, 6, and 7). First, small changes in the chemical
structure of agonists (e.g. the orthosteric building block and the
linker chain) strongly influence the affinities for either the
active or the inactive receptor conformation (Figs. 5 and 6).
Second, an allosteric triplemutant disrupts the purely allosteric
binding topography of the agonists and thus fully rescues ago-
nist efficacy (Fig. 7). Third, a putatively dualsteric agonist (iper-
rigid-naph), which was designed based on our findings, adopts
only the dualsteric binding pose and hence displays full ago-
nism (Fig. 8). Our data show that the population size of inactive
agonistreceptor complexes determines overall agonist efficacy.
In addition to these experimental observations, Onaran and
Costa (45) and others (46, 47) have devised probabilisticmodels
to theoretically describe amultitude of different receptor states
called “receptor ensembles.” Using probability partition func-
tions, it can be shown that ligand binding to receptors changes
the frequency distribution of receptor states. This theory
directly implies that a ligand would have different affinities for
different receptor conformations (47). Interestingly, probabi-
listic models do not distinguish between the chemical natures
FIGURE 8.Rational design of a full agonistwith exclusive dualsteric binding topography. a, transmembrane viewof a representative conformation of the
M2AChR in complexwith iper-rigid-naph in the dualsteric bindingmode taken from a 50-nsMD simulation. Agonisticmoieties are shownwith a green surface;
antagonisticmoieties are shownwith a cyan surface.b, iper-rigid-naph cannotbind in apurely allostericmode like iper-6-naph (Fig. 3c) becauseof the rigidified
linker that is not able to enter the allosteric binding site. The maximum dilatation of the allosteric vestibule is shown as the distance between Thr-842.65 and
Thr-1875.39 (lower green line in b). This conformational constraint allows iper-rigid-naph to only bind in the dualsteric mode. c, effects of iper-rigid-naph on
[3H]NMS equilibrium binding in HEPES buffer (orange curve) and iper-rigid-naph-induced G protein activation (green curve). [3H]NMS and [35S]GTPS binding
areplottedon the left and right ordinates, respectively. Data aremean S.E. from five tonine independent experiments conducted in triplicate.d, the fractional
population of activeM2AChRs (factive) stabilizedby iper-rigid-naph (orange bar) and itsmaximal efficacy (Emax;green bar) relative toAChwere plottedon the left
and right ordinates, respectively. factive was retrieved by fitting all data points in c globally to an operational model of agonism for dynamic ligands (see
“Experimental Procedures”). Error bars represent S.E.
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of ligands or the binding sites that these ligands target prefer-
entially. Hence, in principal, every ligand for GPCRs should
have amultitude ofmicroaffinities for different conformational
states of the receptor. However, it is not known whether differ-
ent agonist affinities go along with different agonist binding
modes. To address this question experimentally, we have stud-
ied a special case of GPCR agonism because the rather extreme
molecular nature of dualsteric agonists allows identifying mul-
tiple agonist binding modes with currently available tech-
niques. Identifying multiple binding topographies of purely
orthosteric agonists by crystallography appears to be techni-
cally challenging as less preferred or energetically less stable
agonistreceptor complexes may not be retrieved easily in crys-
tallization trials. Moreover, subtle differences in the agonist
topography might exceed the resolution currently achieved.
Although structural data of agonists bound to inactive state
receptors have been reported (48, 49), it is not known whether
the agonists in these structures would adopt a different binding
mode in the active state receptors. Furthermore, conventional
molecular docking experiments seem unapt to describe such
dynamic phenomena because they aim at predicting a single,
most favorable conformation of the proteinligand complex.
However, it is tempting to hypothesize that ligand binding
ensembles indeed represent amore generalmechanism for par-
tial agonism. In agreement with probabilistic models of recep-
tor ensembles (45, 46), the conclusions drawn from this study
should not be limited to bitopic agonists. In particular, our data
suggest that it is of worth to study the existence of multiple
bindingmodes of agonists that target only the orthosteric bind-
ing site. Our mechanistic model is supported by previously
published data: the endogenousmuscarinic AChR agonist ACh
has been suggested to adopt both “productive” (i.e. signaling-
competent) and “non-productive” binding modes in the
orthosteric site of M1AChRs (50). Moreover, for ligand-acti-
vated nuclear receptors, ligand binding ensembles have been
crystallized (51–55) and might hence appear as a general prin-
ciple in protein-ligand interactions. In the case of GPCRs, bio-
physical techniques, single molecule studies, and the dyno-
phore approach may be helpful to address whether purely
orthosteric agonists can form a ligand binding ensemble con-
sisting of active and inactive agonistreceptor complexes.
Taken together, the combination of pharmacological exper-
iments and computational simulations based on the inactive
and active M2AChR crystal structures have led to a molecular
description of an agonist binding ensemble. This is a proof of
principle that active and inactive agonistreceptor complexes
can be bound by an agonist in different binding modes. The
concept of ligand binding ensemblesmay be applicable to other
GPCRs and receptor classes.
Experimental Procedures
Materials, Chemical Probes, and Buffers—All cell culture
media and supplements were purchased form Sigma-Aldrich
and Invitrogen. All buffer reagents were from Sigma-Aldrich,
Gru¨ssing GmbH Analytika (Filsum, Germany), and Merck
Labor und Chemie Vertrieb GmbH (Bruchsal, Germany).
[3H]NMS and [35S]GTPS were purchased from PerkinElmer
Life Sciences. ACh, atropine, and NMS were obtained from
Sigma-Aldrich. Iperoxo (56), Isox (57), 6-naph (25), iper-6-
naph (25), isox-6-naph (58), and iper-8-naph (26) have been
synthesized exactly as described previously. The synthesis of
iper-rigid-naph is described in the supplemental information.
Binding buffer A consisted of 10mMHEPES, 10mMMgCl2, 100
mM NaCl, pH 7.4, and binding buffer B was composed of 5 mM
Na, K, Pi, pH 7.4.
Site-directed Mutagenesis and Generation of Stable Cell
Lines—The allosteric triple mutant hM2Y177A,W422A,T423A was
generated by site-directedmutagenesis (QuikChange kit (Strat-
agene, La Jolla, CA)) following the manufacturer’s instructions.
The cDNA of the allosteric double mutant hM2Y177A,W422A in
pcDNA5/FRT was used as the template. The forward and
reverse primers for induction of the T423A mutation by PCR
were as follows (the underlined nucleotides indicate the
mutated triplet): 5-CCCCAACACTGTGGCGGCAATTG-
GTTACTGGC-3 (forward) and 5-GCCAGTAACCAATT-
GCCGCCACAGTGTTGGGG-3 (reverse). The resulting con-
struct was verified by sequencing. The stable Chinese hamster
ovary (CHO)-Flp-InTM cell line expressing the triple mutant
was generated according to the manufacturer’s instructions
(Flp-In system, Invitrogen).
Cell Culture—Flp-In cells (Flp-In-CHO) stably express-
ing the hM2 receptor (CHO-hM2 wild type) or the
hM2Y177A,W422A,T423A triplemutant receptor (CHO-hM2 triple
mutant) were cultured in Ham’s nutrient mixture F-12 supple-
mented with 10% (v/v) fetal bovine serum (FBS), 100 g/ml
streptomycin, 100 units/ml penicillin, and 2 mM L-glutamine.
Cells were grown at 37 °C in a 5% CO2 humidified incubator.
Membrane Preparation—When stably transfected CHO cells
had reachedabout80–90%confluence, themediumwasaspirated
and replaced by freshmedium containing 5mM sodium butyrate,
and cells were incubated for another 16–18 h before membrane
preparation. Medium was aspirated, and 2.4 ml of ice-cold har-
vesting buffer (20 mM HEPES, 10 mM Na2EDTA, pH 7.4) was
added to the cells. Cells were detached from the culture dish using
a cell scraper (Sarstedt, Newton, NC). The cell suspension was
shredded twice for 20 s at level 6 using a Polytron homogenizer,
and the resulting cell fragmentswere centrifuged at 40,000 g for
10 min (4 °C). The supernatant was aspirated, and the pellet was
resuspended in 15 ml of ice-cold centrifugation buffer (20 mM
HEPES, 0.1 mM Na2EDTA, pH 7.4) before centrifugation in con-
ditions mentioned above. This step was repeated once, and the
remaining pellet was resuspended in ice-cold HEPES buffer (12.5
mM HEPES, 12.5 mM MgCl2, 125 mM NaCl, pH 7.4), quickly fro-
zen, and stored in aliquots at80 °C. The protein concentration
was determined by themethod of Lowry (71).
[3H]NMS Equilibrium Binding—CHO-hM2 wild type and
triple mutant membrane homogenates (15–20 g/ml) were
incubated in binding buffer A or B supplemented with GDP
(100 M), the radioligand [3H]NMS (0.2 nM/well), and the test
compounds at different concentrations for 18 h at 30 °C. The
incubation time was calculated as described previously (41).
Atropine (10 M) was used to determine unspecific binding.
The assay was terminated by rapid vacuum filtration. All exper-
iments were carried out in a 96-well microtiter plate (Thermo
Scientific Abgene, Germany) in a final volume of 500 l/well.
Membrane-bound radioactivity was separated from non-
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bound radioligand by vacuum filtration using the TomTec fil-
tration machine. The filter mats (Printed Filtermat A for use
with 1450MicroBetaTM, glass fiber filter, PerkinElmer Life Sci-
ences) were then washed twice with ice-cold distilled water,
further dried for 2.5 min in a microwave, and covered with
melt-on scintillator sheets (MeltiLexTM melt-on scintillator
sheets, PerkinElmer Life Sciences) on a heating block. The filter
mats were then transferred into a plastic sample bag (Sample
Bag for MicroBetaTM, PerkinElmer Life Sciences) and placed
into a reading cassette. Finally, a solid scintillation counter
(Beckman Instruments, Palo Alto, CA) was used to quantify the
radioactivity on the filter mats.
[35S]GTPS Binding—CHO-hM2wild type and triplemutant
membrane homogenates (40 g/ml) were incubated with
[35S]GTPS (0.07 nM) in binding buffer A supplemented with
GDP (10 M). Ligand-induced [35S]GTPS accumulation was
determined after incubation for 1 h at 30 °C.
Pharmacological Data Analysis and Calculations—Analyses
of all concentration-effect curves were performed using Prism
5.01 (GraphPad Software, San Diego, CA). Data points of equi-
librium binding experiments of all orthosteric ligands to the
M2WT and M2 triple mutant receptors were fitted by a four-
parameter logistic function. The resulting IC50 values were
converted into apparent affinity constants, Ki, using the
methodofCheng-Prusoff (59).Data points of equilibriumbind-
ing experiments of all allosteric ligands to the M2WT and M2
triple mutant receptors were fitted by the allosteric ternary
complex model as described previously (25, 26, 28, 60). This
yielded the affinity of the allosteric ligand to free receptors and
its cooperativity  with the radioligand [3H]NMS.
The pharmacological parameters of dynamic ligand binding
were determined by fitting [35S]GTPS binding and [3H]NMS
equilibrium binding data globally using the following system of
equations.
Part I: Y Basal	
Emax
 Basal
1	 EC50[X] 
n (Eq. 1)
Part II: Y Basal	
EmaxBasal
1
([AB]Kobs)
n
[AB]n  dyn
n
(Eq. 2)
where
Kobs
KA  KB
KA	 KB
(Eq. 3)
and
dyn maxfactive (Eq. 4)
Part III:Y
RT  	L

	L
	 KX
(Eq. 5)
in which
RT  B0 
KL 	 	L

	L

(Eq. 6)
and
KX  KL 
Kobs[AB]
Kobs[AB]finactive
(Eq. 7)
where “Basal” and Emax represent the unstimulated (in
the absence of agonist) and maximally ACh-stimulated
[35S]GTPS accumulation (as a surrogate for the maximum
response of the system), respectively. EC50 is the concentration
of the reference ligand ACh that gives the half-maximal
response of the system. [X] is the concentration of the reference
ligand ACh. [AB] is the concentration of the dynamic ligand
AB. n is the slope of the curve. Kobs represents the observed
equilibrium dissociation constant of the dynamic ligand. KA
and KB are the equilibrium dissociation constants of the
dynamic ligand in the active and inactive poses, respectively.
dyn is the dynamic transduction coefficient of the dynamic
ligand and reflects its efficacy. max is the maximal efficacy of
the dynamic ligand that it would have if it was bound to the
receptors exclusively in the active pose. factive is the fraction of
dynamic ligandreceptor complexes in the active pose. RT is the
total number of receptors. B0 is the fraction of binding sites
labeled with [3H]NMS in the absence of competitor. KL is the
equilibrium dissociation constant of the radiotracer [3H]NMS,
and [L] is its concentration.  displays the cooperativity of the
dynamic ligand in the inactive pose with the radiotracer
[3H]NMS. finactive is the fraction of dynamic ligandreceptor
complexes in the inactive pose.
The global fit was set up using Equations 1, 2, and 5 with its
subvariables. For fitting, the following parameters were con-
strained to the indicated values: Basal  0, log EC50 to that of
ACh determined separately for wild type (log EC50  7.27)
and triple mutant receptors (log EC50  5.94), B0  100;
log[L]  9.7, and log KL  9.28.  was constrained to the
cooperativity of the respective allosteric fragment with
[3H]NMS. Emax, Kobs, and n were shared among all data sets.
This global fit yields three parameters, i.e. dyn,Kobs, and finactive.
From those, the remaining parameters can be calculated con-
sequently as follows.
factive 1
 finactive (Eq. 8)
max
dyn
factive
(Eq. 9)
KA 
Kobs
factive
(Eq. 10)
and
KB 
Kobs
finactive
(Eq. 11)
Error propagation was accounted for by using the following
equation.
S.E.(S.E.1)2(S.E.2)2 (Eq. 12)
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Docking, All-atom Molecular Dynamics Simulations, and
Three-dimensional Pharmacophore Analysis—In the presented
study, differentmodeling techniques, such as docking, all-atom
MD simulations, and both static and dynamic three-dimen-
sional pharmacophore analyses, were successfully combined
(36). All protein-ligand docking experiments reported in this
study were carried out with the Cambridge Crystallographic
Data Centre’s software GOLD version 5.1 (61). Prior to the
docking experiments, ligand conformations were generated by
CORINA 3.0 (62). Antagonistic ligand poses were obtained by
docking into the inactive M2AChR crystal structure (Protein
Data Bank code 3UON) (15), and agonistic ligand poses were
obtained by docking into the active M2AChR crystal structure
(Protein Data Bank code 4MQT) (16). Due to the superagonis-
tic properties of the co-crystallized ligand iperoxo, the tyrosine
lid (Tyr-1043.33, Tyr-4036.51, and Tyr-4267.39) strongly sepa-
rates the orthosteric and the allosteric binding sites in the active
crystal structure. Therefore, this tyrosine lid was remodeled by
a side chain sampling based on MD simulations of the apore-
ceptor and the active crystal structure. The preparation of pro-
tein structureswas performedusingMolecularOperating Envi-
ronment (MOE; 2014.09, Chemical Computing Group Inc.).
All ligands and water molecules were removed, and correct
protonation states were assigned. All residues of the inner core
region and the extracellular domains were defined as potential
binding sites (10 Å around the co-crystallized ligands; Protein
Data Bank code 4MQT). Default settings were used for ligand
docking, and GoldScore served as the scoring function. The
obtained docking poses and receptor-ligand interactions were
analyzed using LigandScout 3.1 (63, 64) using a three-dimen-
sional pharmacophore approach.
All MD simulations described in this study were performed
using Desmond 3.2 (65, 66). An orthorhombic box was used to
build the model systems with periodic boundary conditions in
an isothermal–isobaric ensemble with a constant number of
particles. The system temperature was kept at 300 K, and the
pressure was kept at atmospheric pressure. The definition of
transmembrane regions was taken from the OPM database
(67). The receptor structures were embedded in a pre-
equilibrated palmitoyloleoylphosphatidylcholine membrane
(bilayer) and solvated with simple point charge water and
0.15 M NaCl. All other parameters were set on default values.
Each simulation consisted of an equilibration run of 4.52 ns
followed by a production run of 50 ns. The simulations were
carried out on the Soroban computer cluster (Freie Universita¨t
Berlin) by using 24 central processing units. The obtained tra-
jectories were analyzed with the software VMD (68) and
LigandScout 3.1 (63, 64).
Dynamic Three-dimensional Pharmacophores (Dynophores)—
For the comparison of iperoxo and isox as well as their related
dualsteric ligands iper-6-naph and isox-6-naph, respectively,
a novel approach termed dynophore was developed that
combines static three-dimensional pharmacophores with
MD-based conformational sampling. Unlike previous applica-
tions of gathering pharmacophore information frommolecular
dynamics (33, 69), this new implementation works in a fully
automated way: dynophore groups interaction points (such as
hydrogen bonds, charges, and lipophilic contacts) of each tra-
jectory frame according to their type and ligand atoms involved.
All feature groups are graphically represented by three-dimen-
sional volumetric feature density clouds, which are statistically
characterized by occurrence frequency and interaction pat-
terns with the protein. The dynophore algorithm was imple-
mented within the LigandScout framework (63, 64, 70).
Statistical Analysis—Data are shown as mean  S.E. for n
observations. A significant difference between two distinct val-
ues was tested using an unpaired t test. Comparisons of groups
were performed using one-way analysis of variance with Bon-
ferroni’s multiple comparison test.
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